Understanding the XRPN and XRP share valuation gap

Investors looking at Evernorth's XRPN product are noticing a significant valuation discrepancy. Each share of XRPN represents 5.9 tokens of XRP, yet the current market price for these shares often reflects a cost nearly double the actual value of the underlying assets. This premium has sparked debate among traders who are questioning the utility of holding these shares compared to owning the digital asset directly.

There are several reasons why institutional and accredited investors might pay this premium. For many, holding XRPN provides a convenient way to gain exposure to the token within a traditional brokerage account. This avoids the complexities of managing private keys, digital wallets, or navigating the specific security requirements of holding assets on an exchange. The ease of access often commands a high price in the financial world.

Regulatory compliance also plays a major role in the premium. Institutional funds often have strict mandates that prevent them from holding digital assets in their raw form. By purchasing an investment vehicle like XRPN, these entities can satisfy their internal policy requirements while still participating in the price movement of XRP. This creates a persistent demand that keeps the price per share well above the net asset value.

However, potential buyers should be aware of the risks involved. Market premiums can fluctuate wildly based on supply and demand dynamics within the trust. If interest in the product fades, the premium can collapse, leaving investors with losses even if the price of the underlying asset remains stable. It is a classic example of paying for convenience at the expense of capital efficiency.

As the crypto market continues to evolve in 2026, the gap between traditional investment vehicles and direct ownership will likely continue to draw attention. Investors are advised to perform their own calculations regarding the 5.9 token ratio to ensure they understand the exact premium they are paying. While the product offers a regulated path to exposure, the cost of that path remains a significant factor for any rational portfolio strategy.